Disc Medicine Appoints Lisa Amaya Price as Chief HR Officer to Support Commercialization Efforts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Newsfilter
- Leadership Appointment: Disc Medicine has appointed Lisa Amaya Price as Chief Human Resources Officer, leveraging over 25 years of industry experience to drive talent acquisition and development, thereby enhancing the organization's scalability and competitiveness during its commercialization phase.
- Recruitment Strategy Enhancement: As the company progresses towards commercialization, Disc has significantly ramped up hiring efforts, and Lisa's role will be crucial in building a strong team to meet the urgent market demand for new therapies at this pivotal time.
- Equity Incentive Plan: Lisa's inducement equity award includes options for 37,500 shares and 25,000 restricted stock units, designed to attract top talent and ensure long-term commitment, thereby enhancing employee engagement and retention.
- Rich Industry Background: Lisa previously served as Senior Vice President and Chief HR Officer at Deciphera, where she successfully led the integration with ONO Pharmaceuticals, and her extensive experience will provide vital support for Disc's future growth.
Analyst Views on IRON
Wall Street analysts forecast IRON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRON is 120.20 USD with a low forecast of 100.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 77.540
Low
100.00
Averages
120.20
High
154.00
Current: 77.540
Low
100.00
Averages
120.20
High
154.00
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
